Compare ASAN & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASAN | NVAX |
|---|---|---|
| Founded | 2008 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2020 | 1996 |
| Metric | ASAN | NVAX |
|---|---|---|
| Price | $9.81 | $8.52 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 9 |
| Target Price | $10.23 | ★ $14.11 |
| AVG Volume (30 Days) | 4.5M | ★ 6.1M |
| Earning Date | 12-01-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.93 | ★ 309.76 |
| EPS | ★ N/A | N/A |
| Revenue | $790,806,000.00 | ★ $1,123,479,000.00 |
| Revenue This Year | $8.95 | N/A |
| Revenue Next Year | $7.86 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 9.25 | ★ 64.69 |
| 52 Week Low | $5.38 | $6.20 |
| 52 Week High | $15.28 | $13.39 |
| Indicator | ASAN | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 43.22 | 37.52 |
| Support Level | $9.67 | $7.81 |
| Resistance Level | $10.40 | $10.53 |
| Average True Range (ATR) | 0.55 | 0.76 |
| MACD | -0.26 | -0.16 |
| Stochastic Oscillator | 17.81 | 5.98 |
Asana Inc is the system of action for work, built for the Agentic Enterprise. It provides a comprehensive solution where humans and AI agents can collaborate effectively so that individuals work smarter, teams move faster, and organizations deliver results. Companies use Asana to connect their work to company goals and orchestrate mission-critical workflows like product launches, employee onboarding, resource planning, tracking company-wide strategic initiatives and more. It manages its operations and allocates resources as a single operating and reportable segment. The company generates revenues from subscriptions from paying customers accessing its cloud-based platform.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.